CL2024003486A1 - Anticuerpo anti-b7h3 y usos del mismo - Google Patents

Anticuerpo anti-b7h3 y usos del mismo

Info

Publication number
CL2024003486A1
CL2024003486A1 CL2024003486A CL2024003486A CL2024003486A1 CL 2024003486 A1 CL2024003486 A1 CL 2024003486A1 CL 2024003486 A CL2024003486 A CL 2024003486A CL 2024003486 A CL2024003486 A CL 2024003486A CL 2024003486 A1 CL2024003486 A1 CL 2024003486A1
Authority
CL
Chile
Prior art keywords
antibody
antigen
methods
binding portion
binds
Prior art date
Application number
CL2024003486A
Other languages
English (en)
Spanish (es)
Inventor
Rong Naiyan
Wang Zhuozhi
Li Jie
Gu Jijie
Original Assignee
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Ireland Ltd
Publication of CL2024003486A1 publication Critical patent/CL2024003486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2024003486A 2022-05-18 2024-11-14 Anticuerpo anti-b7h3 y usos del mismo CL2024003486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2022093524 2022-05-18

Publications (1)

Publication Number Publication Date
CL2024003486A1 true CL2024003486A1 (es) 2025-06-13

Family

ID=88834684

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024003486A CL2024003486A1 (es) 2022-05-18 2024-11-14 Anticuerpo anti-b7h3 y usos del mismo

Country Status (12)

Country Link
US (1) US20250313633A1 (enExample)
EP (1) EP4526346A1 (enExample)
JP (1) JP2025517737A (enExample)
KR (1) KR20250011957A (enExample)
CN (1) CN119256010A (enExample)
AU (1) AU2023273853A1 (enExample)
CA (1) CA3253563A1 (enExample)
CL (1) CL2024003486A1 (enExample)
IL (1) IL316510A (enExample)
MX (1) MX2024014232A (enExample)
TW (1) TW202402808A (enExample)
WO (1) WO2023222017A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118829656B (zh) * 2023-12-01 2026-04-24 苏州智核生物医药科技有限公司 B7h3结合多肽及其用途
WO2025157244A1 (zh) * 2024-01-25 2025-07-31 山东先声生物制药有限公司 抗b7h3抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2015306621B2 (en) * 2014-08-27 2021-05-06 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
UA125593C2 (uk) * 2017-03-31 2022-04-27 Джянгсу Хенгруй Медісін Ко., Лтд. Антитіло в7-н3, його антигензв'язуючий фрагмент та його медичне застосування
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN112851812B (zh) * 2020-06-30 2021-09-14 广州百暨基因科技有限公司 抗b7h3抗体及其应用
CN113402610B (zh) * 2021-06-09 2023-02-24 英诺湖医药(杭州)有限公司 一组b7h3单克隆抗体及其医药用途
CN113336851B (zh) * 2021-06-30 2021-12-24 徐州医科大学 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用

Also Published As

Publication number Publication date
CA3253563A1 (en) 2023-11-23
WO2023222017A1 (en) 2023-11-23
US20250313633A1 (en) 2025-10-09
CN119256010A (zh) 2025-01-03
JP2025517737A (ja) 2025-06-10
TW202402808A (zh) 2024-01-16
MX2024014232A (es) 2025-03-07
AU2023273853A1 (en) 2024-10-24
EP4526346A1 (en) 2025-03-26
KR20250011957A (ko) 2025-01-22
IL316510A (en) 2024-12-01

Similar Documents

Publication Publication Date Title
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
CO2021007053A2 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
MX2020014158A (es) Anticuerpos anti proteína de muerte programada 1 (pd-1) y usos de estos.
CU24568B1 (es) Anticuerpo inhibidor de masp-3
CL2019000658A1 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo.
MX2022007676A (es) Anticuerpos caninizados biespecificos para tratar dermatitis atopica.
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
CO2019002370A2 (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
CL2021000146A1 (es) Anticuerpos humanizados contra psma
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
BR112021020924A2 (pt) Uso de um anticorpo anti-cd19 para tratar doença autoimune
MX2021003298A (es) Métodos para revertir la actividad ticagrelor.
CL2022002829A1 (es) Anticuerpo anti-ox40 y usos del mismo
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
MX2019000539A (es) Anticuerpos anti-il-22r.
MX2024014232A (es) Anticuerpo anti-b7h3 y usos del mismo
CO2022010204A2 (es) Anticuerpos contra la integrina alfa 11 beta 1
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
MX2025009475A (es) Anticuerpo anti-cntn4 y usos de este
CL2022000752A1 (es) Molécula de unión específica para lif y uso de la misma
MX2021002647A (es) Metodos de tratamiento de la psoriasis.
PE20230765A1 (es) Anticuerpo anti-cd47 y usos del mismo